Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Pharma companies should be lining up to partner with us
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Mole101on Jun 07, 2021 6:23pm
124 Views
Post# 33345087

RE:Pharma companies should be lining up to partner with us

RE:Pharma companies should be lining up to partner with us

I would just be happy with Biogen deciding to throw some cash at us for a little piece of the pie, it would make sense to try to improved their product and PMN could be the solution ( I'm just dreaming) ..but I would be happy with any partnerships 

JoeyBoston wrote: Today's decision was huge as it gave the green light to invest in the amyloid hypothesis to fight AD. All players in this space, not just Biogen, went up big including Eli Lilly.

Seems like big pharma would be lining up to partner with or buy-out/merge with Promis. Throw in Cashman's platform and how that is working to combat Covid, and this company has to be worth a few Billion today or in the near fiture.  

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities